- Brand names:
- Pharmaceutical Company:
- Condition/Indication: High risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 938KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 77KB)
Decitabine with cedazuridine – July 2021
Decitabine with cedazuridine: Tablet containing decitabine 35 mg + cedazuridine 100 mg; Inqovi®
Last updated
29 October 2021